Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile
Go back to Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile| (NYSE: BHVN) | Delayed: 15.34 +1.77 (13.04%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $13.57 | 52 Week High | $ | |||
| Open | $14.07 | 52 Week Low | $ | |||
| Day High | $15.40 | P/E | N/A | |||
| Day Low | $14.07 | EPS | $ | |||
| Volume | 1,053,571 | |||||
